ArticleCureus2025
Acute Encephalopathy and Severe Hypercalcemia as the Initial Presentation of a Large Parathyroid Hormone-Related Protein (PTHrP)-Secreting Pancreatic Neuroendocrine Tumor: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic neuroendocrine tumors (pNETs) are rare neoplasms that present with diverse clinical manifestations depending on their secretory activity. Paraneoplastic hypercalcemia due to parathyroid hormone-related peptide (PTHrP) secretion by pNETs is an uncommon but serious complication. We describe the case of a 67-year-old female with a past medical history of multiple sclerosis and uveitis presenting with acute metabolic encephalopathy due to profound hypercalcemia. Laboratory workup revealed a corrected calcium of 22.4 mg/dL and PTHrP of 327 pg/mL. Imaging demonstrated a new 15 cm pancreatic mass with adrenal nodules suspicious for metastatic disease. Pathology from a percutaneous biopsy confirmed a well-differentiated pNET with a Ki-67 index of ~15%. The patient's mental status improved following treatment of hypercalcemia with intravenous hydration, calcitonin, zoledronic acid, and urgent hemodialysis. She was started on lanreotide therapy for pNET treatment. This case highlights the importance of considering pNETs in the differential diagnosis of unexplained hypercalcemia, as timely recognition and management can reverse neurologic dysfunction and improve outcomes. Awareness of this rare presentation may facilitate earlier diagnosis and treatment of underlying neuroendocrine malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.